Irritable Bowel Syndrome Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Adults and adolescents (≥18 years for most pharmacological protocols; pediatric IBS managed separately) with a Rome IV–confirmed diagnosis of IBS-C, IBS-D, IBS-M, or IBS-U

• Patients who have failed first-line dietary and lifestyle modifications for ≥3–6 months without adequate symptom relief

• Patients with refractory IBS seeking second or third-line pharmacological or psychological interventions not accessible or affordable in their home country

• Patients requiring diagnostic exclusion of organic disease (IBD, colorectal cancer, celiac disease, microscopic colitis) prior to IBS management

• Patients with post-infectious IBS (PI-IBS) with documented gastroenteritis history seeking targeted antibiotic or microbiome therapy

• International patients seeking Low-FODMAP dietitian programs, gut-directed CBT, or gut-directed hypnotherapy in structured multidisciplinary settings

• REQUIRED DIAGNOSTIC WORKUP (performed on arrival or reviewed if pre-existing):

• Complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) — to exclude inflammatory conditions

• Fecal calprotectin — highly sensitive marker to distinguish IBS from IBD (cutoff <50 µg/g strongly supports IBS)

• Celiac serology: Anti-tissue transglutaminase IgA (anti-tTG IgA) and total IgA

• Thyroid function tests (TSH, fT4) — thyroid dysfunction can mimic IBS symptoms

• Hydrogen-methane breath test (lactulose or glucose substrate) — to diagnose Small Intestinal Bacterial Overgrowth (SIBO), prevalent in 30–85% of IBS-D patients

• Colonoscopy with random biopsies — indicated for patients >45 years, alarm features (rectal bleeding, unexplained weight loss, nocturnal symptoms, family history of colorectal cancer or IBD), or to exclude microscopic colitis

• Anorectal manometry and balloon expulsion test — indicated in IBS-C to exclude defecatory disorders such as dyssynergic defecation

• Rome IV symptom questionnaire and validated IBS-Symptom Severity Score (IBS-SSS) for baseline severity stratification

• Psychological screening: PHQ-9 (depression), GAD-7 (anxiety), as comorbid mood disorders significantly affect treatment outcomes

• CONTRAINDICATIONS / EXCLUSION CRITERIA:

• Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) — requires distinct management pathway

• Confirmed colorectal malignancy or high-grade dysplasia — requires oncological referral

• Celiac disease with active gluten exposure — requires gluten-free diet as primary intervention, not IBS protocols

• Severe psychiatric illness not stabilized — gut-directed psychotherapy requires baseline psychological stability

• Renal impairment (eGFR <30 mL/min/1.73m²) — contraindication to some IBS-C secretagogues (e.g., linaclotide dose adjustment)

• Pregnancy — many pharmacological agents (e.g., rifaximin, alosetron, eluxadoline) are contraindicated; dietary therapy is first-line

• Known organic causes of bowel dysfunction (post-surgical short bowel, pelvic floor structural defects) requiring surgical rather than medical management

IBS management is non-surgical and follows an evidence-based stepwise multimodal approach. Treatment is individualized based on IBS subtype (IBS-C, IBS-D, IBS-M), symptom severity (mild/moderate/severe per IBS-SSS), and the presence of comorbid psychological conditions.

--- STEP 1: DIETARY & LIFESTYLE INTERVENTIONS (First-Line) ---

• Low-FODMAP Diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols): The most robustly evidence-based dietary intervention for IBS, with 50–86% of patients experiencing significant symptom reduction. Conducted in three structured phases: Elimination (2–6 weeks), Reintroduction (systematic FODMAP category re-challenge), and Personalization. Requires supervision by a trained dietitian with IBS expertise. Available in structured outpatient programs at GAF Healthcare partner centers.

• Soluble Fiber Supplementation: Psyllium husk (ispaghula) is recommended for IBS-C and IBS-M (evidence level: strong). Insoluble fiber (wheat bran) may worsen symptoms and is generally avoided.

• Gut-Healthy Lifestyle Counseling: Regular physical activity (150 min/week moderate intensity), sleep hygiene, and stress reduction strategies — all evidence-based adjuncts.

• Probiotics: Specific strains with evidence include Bifidobacterium infantis 35624, Lactobacillus plantarum 299v, and multi-strain preparations. Used as adjunct therapy; response is strain-specific and patient-variable.

--- STEP 2: GUT-DIRECTED PHARMACOTHERAPY (Second-Line) ---

For IBS-D (Diarrhea-Predominant):

• Antidiarrheal agents: Loperamide (reduces stool frequency and urgency; does not improve pain or global IBS symptoms)

• Gut-selective antibiotic: Rifaximin (Xifaxan) — a minimally absorbed, gut-selective antibiotic targeting luminal dysbiosis. FDA-approved for IBS-D. Standard protocol: 550 mg TID × 14 days. Approximately 40–50% of patients achieve global symptom relief; repeat courses are effective.

• 5-HT3 antagonists: Ondansetron (off-label, effective for stool consistency and frequency in IBS-D); Alosetron (FDA-approved for severe IBS-D in women; Risk Evaluation and Mitigation Strategy [REMS] program required due to rare ischemic colitis risk)

• Mixed opioid agonist/antagonist: Eluxadoline (Viberzi) — FDA-approved for IBS-D; acts locally on µ- and κ-opioid receptors and as a δ-opioid antagonist; contraindicated in patients without a gallbladder or with known/suspected sphincter of Oddi dysfunction or alcohol use disorder

• Bile acid sequestrants: Colesevelam or cholestyramine — for IBS-D patients with evidence of bile acid malabsorption (SeHCAT test <15% retention)

For IBS-C (Constipation-Predominant):

• Osmotic laxatives: Polyethylene glycol (PEG/Macrogol) — improves stool frequency but evidence for abdominal pain relief is limited

• Secretagogues (intestinal secretory agents):

- Linaclotide (Linzess): Guanylate cyclase-C (GC-C) agonist; FDA-approved for IBS-C; 290 µg daily; reduces abdominal pain and improves bowel frequency via increased intestinal fluid secretion and direct visceral analgesic effect on colonic afferent neurons

- Plecanatide (Trulance): Second-generation GC-C agonist; 3 mg daily; similar mechanism to linaclotide

- Lubiprostone (Amitiza): Chloride channel activator (ClC-2); FDA-approved for IBS-C in women ≥18 years; 8 µg BID

- Tenapanor (Ibsrela): NHE3 sodium/hydrogen exchanger inhibitor; reduces intestinal sodium absorption, increasing water content of stool; FDA-approved for IBS-C; 50 mg BID

• Prokinetics: Prucalopride (selective 5-HT4 agonist) — approved for chronic constipation with emerging evidence in IBS-C

For IBS with Global Symptoms / Pain-Predominant:

• Antispasmodics: Hyoscine butylbromide (Buscopan), dicyclomine, otilonium bromide, mebeverine — reduce colonic smooth muscle spasm; effective for postprandial pain

• Peppermint oil (enteric-coated): L-menthol acts as a calcium channel blocker on intestinal smooth muscle; evidence-based antispasmodic with good tolerability

--- STEP 3: NEUROMODULATORS (Pain-Refractory IBS) ---

• Tricyclic Antidepressants (TCAs): Amitriptyline (10–75 mg nocte), nortriptyline — used for central and peripheral pain modulation; evidence level: strong (ACG 2021 Conditional Recommendation). Analgesic effect independent of antidepressant effect; onset 4–6 weeks

• Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, paroxetine — primarily for IBS-C with comorbid depression/anxiety; limited direct IBS efficacy data

• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Duloxetine — emerging evidence for centrally mediated visceral pain in IBS

--- STEP 4: GUT-DIRECTED PSYCHOTHERAPY (Refractory / Severe IBS) ---

• Gut-Directed Cognitive Behavioral Therapy (GD-CBT): Strongly recommended by ACG 2021 guidelines (Conditional Recommendation, moderate-quality evidence). Targets catastrophizing, hypervigilance, and maladaptive illness behaviors. Delivered over 6–12 structured sessions. Available face-to-face and via digital CBT platforms.

• Gut-Directed Hypnotherapy (GDH): Pioneered by Professor Peter Whorwell (Manchester model). 7–12 sessions of gut-focused hypnosis inducing deep relaxation and positive gut imagery. Evidence shows 70–80% response rates in refractory IBS; effects sustained at 5-year follow-up. Available at selected GAF Healthcare partner centers.

• Mindfulness-Based Stress Reduction (MBSR): 8-week structured program reducing psychological distress and visceral hypersensitivity.

--- STEP 5: EMERGING & ADVANCED THERAPIES ---

• Fecal Microbiota Transplantation (FMT): Under active investigation for IBS-D; Phase III trial data mixed; currently considered investigational for IBS (approved at select research-active centers)

• SIBO-targeted therapy: Sequential antibiotic protocols (rifaximin ± neomycin for methane-dominant SIBO) guided by hydrogen-methane breath test results; elemental diet as bridge therapy

• Capsule Endoscopy (PillCam): For diagnostic exclusion of Crohn's disease in patients with alarm features where conventional endoscopy is inconclusive

• Anorectal Biofeedback Therapy: Recommended for IBS-C patients with concurrent dyssynergic defecation confirmed on anorectal manometry; 6–8 sessions; remission rates of 70–80%

PHASE 1 — PRE-TRAVEL PREPARATION (2–4 weeks before departure):

• Step 1: Submit medical records to GAF Healthcare coordinator via secure portal (previous colonoscopy/endoscopy reports, blood work, imaging, current medications, and completed Rome IV symptom questionnaire and IBS-SSS)

• Step 2: GAF Healthcare medical team conducts virtual pre-consultation with the assigned gastroenterologist (India or UAE) to review records, confirm diagnosis, identify diagnostic gaps, and outline a personalized treatment plan

• Step 3: GAF Healthcare arranges e-Medical Visa (India) or UAE entry visa documentation, airport transfer scheduling, and hospital appointment coordination

• Step 4: Patient begins Low-FODMAP elimination phase under dietitian guidance (can be initiated remotely via GAF-partnered telehealth dietitian)

PHASE 2 — ARRIVAL & DIAGNOSTIC WORKUP (Days 1–4):

• Day 1: Airport transfer to hotel/hospital accommodation; check-in; rest

• Day 2: Comprehensive gastroenterology consultation with senior specialist. Physical examination, Rome IV confirmation, IBS-SSS baseline score, PHQ-9/GAD-7 psychological screening. Blood draws: CBC, CRP, ESR, fecal calprotectin, celiac serology, thyroid function, and stool culture/ova/parasites

• Day 3: Hydrogen-methane breath test (fasting, 3-hour protocol) for SIBO. Dietary assessment with specialist IBS dietitian (Low-FODMAP audit and personalization). If anorectal manometry indicated (IBS-C with suspected defecatory disorder): performed on this day (30-minute outpatient procedure, no sedation required)

• Day 4: Colonoscopy with biopsies if indicated (for patients >45 years or with alarm features). Performed under conscious sedation or propofol sedation. Patient recovers for 1–2 hours post-procedure; discharged same day. Biopsy results typically available within 24–72 hours at accredited partner centers

PHASE 3 — TREATMENT INITIATION (Days 4–10):

• Day 5: Diagnostic results review with gastroenterologist. Finalization of personalized multimodal treatment plan. Prescription of appropriate pharmacotherapy (e.g., rifaximin 550 mg TID × 14 days for IBS-D/SIBO; linaclotide 290 µg for IBS-C; amitriptyline 10–25 mg for pain-refractory IBS). Medication counseling provided by clinical pharmacist

• Days 5–10: Structured Low-FODMAP program continues with in-person or virtual dietitian sessions. First 2–3 sessions of gut-directed CBT or gut-directed hypnotherapy if enrolled (available at select partner centers). Anorectal biofeedback sessions scheduled if applicable (typically 3 sessions can be completed during stay)

• Day 7–10 (if SIBO confirmed): Rifaximin course actively ongoing; dietary modifications for methane vs. hydrogen-dominant SIBO implemented

PHASE 4 — FOLLOW-UP & DISCHARGE PLANNING (Days 10–14):

• Day 10–12: Follow-up consultation. IBS-SSS reassessment. Review of colonoscopy biopsy results (celiac confirmation, microscopic colitis status). Adjustment of pharmacotherapy if needed. Comprehensive discharge summary prepared in English (and translated if requested)

• Day 12–14: Discharge package prepared: full written management plan (dietary plan, medication regimen with tapering instructions, probiotic protocol), contact details of treating gastroenterologist for remote follow-up, referral letter to home-country physician, and 90-day telemedicine follow-up plan via GAF Healthcare platform

• Fit-to-Fly Clearance: Most IBS patients are medically fit to travel by Day 10–14. No surgical wound or mobility restrictions apply; fitness for flight is based on absence of active diagnostic procedures or ongoing sedation-based treatments

PHASE 5 — REMOTE FOLLOW-UP (Months 1–3):

• Week 4: Telemedicine review with gastroenterologist (symptom response assessment, IBS-SSS re-score, medication review)

• Week 8–12: Structured Low-FODMAP reintroduction guidance via telehealth dietitian; identification of personal FODMAP triggers

• Month 3: Comprehensive remote review; decision on continuation, dose adjustment, or addition of gut-directed psychotherapy (which can be accessed locally or via validated digital platforms such as Zemedy, Nerva, or Mahana IBS)